Adicet Bio Obtains $51,000,000 Series A Funding
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=6927f2d0-2c43-4e15-95dc-c9a6440df2ee - Date
1/28/2016 - Company Name
Adicet Bio - Mailing Address
Undisclosed Menlo Park, CA 94025 USA - Company Description
Adicet Bio, Inc. is a biotechnology company engaged in the design and development of cutting-edge immunotherapies for cancer and other disease indications, with a focus on novel universal immune cell therapies (uICT). - Website
Undisclosed
- Transaction Type
Venture Equity - Transaction Amount
$51,000,000 - Transaction Round
Series A - Proceeds Purposes
These significant financial resources will allow Adicet to progress its universal immune cell therapy (uICT) platform technology and related products and advance AIT’s programs and product pipeline. - M&A Terms
- Venture Investor
OrbiMed - Venture Investor
Novartis Venture Fund - Venture Investor
Pontifax Fund
